BCL2 and leukemia: This assumption is in line with previous studies showing that treatment with N-acetyl cysteine, which exerts antioxidant activity by augmenting cellular thiols, reduces DSBs and facilitates non-homologous end joining repair in bone marrow cells in a murine NRAS/BCL2-related model of leukemia [22].